tooluniverse-pharmacovigilance

Analyzes drug safety signals from FAERS, FDA labels, and pharmacogenomic databases into structured reports.

Updated Mar 13, 2026
One-click install
npx skills add https://github.com/matt-grain/pharma-catalyst --skill tooluniverse-pharmacovigilance-matt-grain
Or copy as Structured Prompt for Agent▼
Please help me install this Agent Skill.
Skill: tooluniverse-pharmacovigilance
Source: https://github.com/matt-grain/pharma-catalyst/tree/main/.claude/skills/tooluniverse-pharmacovigilance
Command: npx skills add https://github.com/matt-grain/pharma-catalyst --skill tooluniverse-pharmacovigilance-matt-grain

SYSTEM DOCUMENTATION & REQUIREMENTS

What problem does it solve? Manually compiling a drug safety profile requires querying FAERS adverse event data, FDA labeling, PharmGKB pharmacogenomics, and clinical trial results separately, then calculating disproportionality statistics by hand. This Skill automates that multi-source pharmacovigilance workflow into a single structured safety report. ## Core Features & Use Cases - Disproportionality Signal Detection: Queries FAERS adverse event counts and calculates PRR with 95% confidence intervals, applying WHO-UMC signal thresholds and tiering signals T1-T4 by severity. - Multi-Source Triangulation: Combines DailyMed boxed warnings and contraindications, PharmGKB pharmacogenomic variants with evidence levels, ClinicalTrials.gov Phase 3/4 safety data, KEGG pathway context, and PubMed/preprint literature. - Structured Report Generation: Produces a progressive [DRUG]_safety_report.md with 10 sections plus CSV exports of adverse events and pharmacogenomic variants, with mandatory source citations. - Use Case: Ask whether metformin is safe for a patient with mild renal impairment and receive a report covering the lactic acidosis boxed warning, FAERS PRR analysis, renal dosing thresholds, and monitoring recommendations. ## Quick Start Generate a pharmacovigilance safety report for metformin including FAERS adverse event signals, FDA label warnings, and pharmacogenomic risk factors.

Frequently Asked Questions about tooluniverse-pharmacovigilance

High-intent search queries and answers about installing and using this skill.

FAQPage Schema
How do I analyze drug adverse events from FAERS data?▼

Query FAERS_count_reactions_by_drug_event with the drug_name parameter to get ranked adverse event counts, then calculate PRR with 95% confidence intervals for each event. Signals are flagged when PRR exceeds 2.0 with at least 3 cases and a lower confidence bound above 1.0.

How to detect pharmacovigilance signals using disproportionality analysis?▼

Compute the Proportional Reporting Ratio as (A/B)/(C/D) from a 2x2 contingency table of drug-event reports. Apply WHO-UMC criteria: PRR at least 2, chi-squared above 4, and case count of 3 or more, then score signals by PRR times severity weight times log case count.

What data sources does this drug safety analysis use?▼

It combines FAERS and OpenFDA adverse event reports, DailyMed structured product labels for boxed warnings and contraindications, PharmGKB and CPIC pharmacogenomic annotations, ClinicalTrials.gov Phase 3/4 results, KEGG pathways, and PubMed plus preprint literature.

Can I compare safety profiles of two drugs?▼

Yes, the workflow supports head-to-head comparison by querying FAERS for both drugs over the same time period and aligning shared adverse events by PRR. The output includes comparison tables for bleeding, GI tolerability, or other event classes with a stated recommendation.

What are the limitations of FAERS-based safety analysis?▼

FAERS suffers from underreporting, reporting bias from media attention, and confounding by comorbidities, so PRR is a relative disproportionality measure rather than a true incidence rate. Results should be triangulated with clinical trial data and label information before drawing conclusions.